Mechanisms of thrombus formation and lysis

Annals of Emergency Medicine

Volumn 17, Issue 11, 1988, Pages 1138-1147

  Stump, David C ^a   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

formation; thrombus

Indexed keywords

FIBRINOLYTIC AGENT;

BLOOD CLOTTING; FIBRINOLYSIS; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW;

BLOOD COAGULATION; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; FIBRIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMAN; PLASMINOGEN; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 0023689802     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-0644(88)80059-3     Document Type: Article

References (73)

1. Mechanism of non-adhesiveness of endothelial and epithelial surfaces
2. 2 and arachidonic acid to prostacyclin by cultured human endothelial cells
3. Identification of endothelial cell cofactor for thrombin catalyzed activation of protein C
4. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated Factor V
5. The anticoagulant effect of heparin sulfate and dermatan sulfate
6. Latent tissue plasminogen activator produced by human endothelial cells in culture: Evidence for an enzyme inhibitor complex
7. The adhesion of platelets to subendothelium, collagen and artificial surfaces
8. Platelet adhesion
9. Endothelial cell procoagulant properties and the host response
10. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation
11. Human platelet membrane receptor for bovine von Willebrand factor (platelet aggregating factor): An integral membrane glycoprotein
12. Secretable storage pools in platelets
13. Inositol triphosphate and diacylglyerol as second messengers
14. The role of protein kinase C in cell surface signal transduction and tumor promotion
15. Molecular defects in interactions of platelets with the vessel wall
16. Coordinate binding of factor Xa to the unstimulated platelet
17. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier
18. Waterfall sequence for intrinsic blood clotting
19. Platelet involvement in coagulation
20. Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway: Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor
21. a in the activation of bovine factor X
22. Functional prothrombinase complex assembly on isolated monocytes and lymphocytes
23. Prothrombinase complex assembly: Kinetic mechanism of enzyme assembly on phospholipid vesicles
24. The purification and mechanism of action of human antithrombin-heparin cofactor
25. Inherited antithrombin deficiency causing thrombophilia
26. Deficiency of protein C in congenital thrombotic disease
27. Do patients with thromboembolic disease have circulating platelet aggregates?
28. The hypercoagulable states
29. The molecular structure of fibrinogen
30. Fibrin: Structure and interactions
31. Human factor XIII from plasma and platelets: Molecular weights, subunit structure, proteolytic activation and cross-linking of fibrinogen and fibrin
32. Characterization and comparison of macromolecular end products of fibrinogen and fibrin proteolysis by plasmin
33. Plasmic degradation of crosslinked fibrin: Characterization of new macromolecular soluble complexes and a model of their structure
34. On the kinetics of the reaction between human antiplasmin and plasmin
35. Amino acid sequence studies on plasmin-derived fragments of human fibrinogen: Amino-terminal sequences of intermediate and terminal fragments
36. The primary structure of human plasminogen: Isolation of two lysine-binding fragments and one “miniplasminogen (M.W. 38,000) by elastase-catalyzed-specific limited proteolysis
37. The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen
38. Mechanism of activation of human plasminogen by the activator complex streptokinase-plasmin
39. 2-antiplasmin
40. Thrombolytic therapy and streptokinase using a standard dosage scheme
41. The surface-mediated initiation of blood coagulation and related phenomena
42. Cloning and expression of human tissue-type plasminogen activator cDNA in E coli
43. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay
44. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture
45. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells
46. The primary structure of high molecular mass urokinase from human urine
47. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine
48. Isolation and characterization of urokinase from human plasma
49. 2-antiplasmin consumption and fibrinogen breakdown during thrombolytic therapy
50. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis
51. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species
52. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin
53. Activation of plasminogen by pro-urokinase I Mechanism
54. Urokinase-related proteins in human urine. Isolation and characterization of single chain urokinase (pro-urokinase) and urokinase-inhibitor complex
55. Biological and thrombolytic properties of proenzyme and active forms of urokinase: I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology
56. Comparative thrombolytic properties of single chain forms of urokinase-type plasminogen activator
57. Purification and characterization of a novel low molecular weight form of single chain urokinase-type plasminogen activator
58. Characterization of the functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies
59. Human tissue-type plasminogen activator from the laboratory to the bedside
60. Biochemical and biological properties of single chain urokinase-type plasminogen activator
61. Fibrinolysis during liver transplantation in humans: Role of tissue-type plasminogen activator
62. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma
63. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells
64. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets
65. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients
66. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor
67. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma
68. Increased levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
69. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies
70. Urokinase inhibitor in human placenta
71. Purification and characterization of a novel inhibitor of urokinase from human urine. Quantitation and preliminary characterization in plasma
72. In vivo synergism of thrombolytic agents
73. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents